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The Therapeutic Management of Back Pain With and Without Sciatica in the Emergency department: 
A Systematic review 
 
Running title 
Back pain in the Emergency Department 
 
Introduction 
There were 23.8 million attendances in Emergency Departments (ED) in England in 2017-18 (1). The 
number of patients re-attending within 7 days in 2018-18 was 1.7 million; this is an overall increase 
since 2008-09 of 86 percent.  This is impacting on the National Health Service (NHS) constitution 
target of 95 percent of patients spending 4 hours or less in the ED, which has not been met since 
2013-14 (1). 
There are no specific data pertaining to numbers of patients with low back pain, with or without 
sciatica, attending the ED in the United Kingdom (UK) due to recording of diagnostic categories in 
national statistics not specifying the anatomical region of musculoskeletal problems. Epidemiological 
data from the United States of America (USA) have reported an estimated 2.06 million episodes of 
low back pain per year, accounting for 3% of all emergency department visits (2). In Australia, back 
pain is reported to be in the top 10 conditions presenting in the ED (3). In most ED back pain cases , 
despite increasing use of diagnostic tests, such as plain film radiographs, Magnetic Resonance 
Imaging (MRI) scans and blood tests with direct costs estimated at US$819 million (4), the specific 
cause of patient symptoms is never established (5, 6). The lack of diagnosis and management 
guidelines results in significant physical and emotional burden to the patient and challenge to the 
treating physician (3).  It is recommended specific imaging modalities be reserved exclusively to 
exclude serious conditions (5).  
In the absence of specific guidance, there is evidence to suggest the existence of varied and 
inconsistent management of back pain with or without sciatica in the ED (6). Although guidelines 
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suggest opioids be reserved for severe pain (7), evidence suggests their use in the ED has increased 
and the use of non-steroidal anti-inflammatories has decreased (4, 5).  
Physiotherapy management of musculoskeletal conditions, has been recommended as a potentially 
clinically and cost effective addition to the ED Multi-Disciplinary Team (MDT) (8). Physiotherapists as 
primary contact practitioners in the ED have demonstrated effective management of back pain with 
or without sciatica, with significantly less ED length of stay (EDLOS) and fewer imaging requests than 
medical staff (9). 
The importance of establishing some recommendations for the management of low back pain with 
or without sciatica in the absence of clinical red flags or serious pathology in the ED would be helpful 
to patients and clinicians. A MDT approach to health care is becoming increasingly commonplace 
and there is a growing body of evidence suggesting that inter-professional teamwork in the ED could 
be beneficial in reducing LOS and unnecessary imaging (8-10).  
Objectives 
The purpose of this study was to review the available literature to determine the evidence base for 
therapeutic management of adults presenting with back pain with or without sciatica in the ED. The 
outcomes of interest included pain, function, EDLOS, adverse events and continued resource 
utilisation such as re-attendance in the ED. 
Method 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were 
taken into account to enhance the quality of this review. The review protocol was made publicly 
available on the PROSPERO website. 
Search Strategy 
The following databases were searched: MEDLINE [via IVIDSP 1946-], EMBASE [via EBSCOhost 1974-
], SCOPUS [1996-], CINAHL [via EBSCOhost 1981-], ZETOC [1993-], PubMed, The Cochrane Library 
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(Cochrane Database of Systematic Reviews), Web of Science, Open Grey and ETHOS. Searches were 
from inception to August 2018. Search terms were (Low Back Pain) OR (Lumbago) OR (Sciatica) OR 
(Radiculopathy) AND (Emergency Department) OR (Accident and Emergency) OR (A&E) AND 
(Treatment) OR (Management) including MeSH. 
Inclusion and exclusion criteria 
Included were, peer reviewed, original research in the English Language. All studies including adult 
patients (> 16 years) with low back pain in the ED with validated outcome measures were included. 
Radicular leg pain could be present or absent. All therapeutic interventions were evaluated. Pilot 
studies were included. 
Studies were excluded if they addressed the management of patients with red flags suggestive of 
serious spinal pathologies such as cauda equina syndrome, cancer or infection, rheumatoid or 
inflammatory arthropathies, pregnancy, low back pain resulting from major trauma and abdominal 
aortic aneurysm. Studies set in primary care, GP surgeries, hospital wards and emergency transport 
were excluded. Studies evaluating diagnostic and imaging interventions were excluded. Other 
exclusions included systematic and narrative reviews, clinical commentaries, editorials, grey 
literature or studies from non-peer reviewed journals. Reference lists of the full text articles were 
checked to ensure any articles not captured in the electronic search were included. No publication 
date limits were set.  
Study selection and quality assessment scheme 
Two reviewers (JA/NR) searched the databases independently. Articles were reviewed for eligibility 
based on their title, abstract and then full text. Non-eligible studies were excluded and duplicate 




Two reviewers (JA/NR) extracted key data from the articles independently and third and fourth 
reviewers (PG/GY) acted as arbiters. Key data were summarised to allow comparison and 
contextualisation of results (Tables 1 and 2). 
Assessment of Study Quality 
 The final studies were appraised for methodological quality by the two reviewers (JA/NR) 
independently using the Downs and Black checklist (11), any disagreement in scores resolved by 
discussion. Third and fourth reviewers (GY/PG) were available to resolve disagreements; however, 
this was not required. The Downs and Black checklist has a Spearman Correlation Coefficient 0.90 for 
assessing the methodological quality of randomized and non-randomized studies (12).  The checklist 
has five sections: reporting, external validity, internal validity, selection bias and power. Each section 
has a maximum score of 11, 3, 7, 6 and 5 points, respectively, or total score of 32 points.  
Results 
An initial search identified 2384 articles on a variety of topics on the ED management of acute low 
back pain with or without sciatica. After removing duplicates and excluding those not matching the 
inclusion criteria, a total of 26 articles were identified including 5429 patients, spanning eight 
countries (Table 1 and 2). The outcome measures, interventions and comparators used in these trials 
were heterogeneous, therefore, a narrative review was deemed be the most appropriate method to 
report the findings. 
Out of the final 26 studies there were 19 randomised control trials, 2 randomised studies (no 
control), one randomised control pilot study, two cohort studies, one cohort pilot study and one 
retrospective audit. 
Figure 1: Flowchart depicting the database search and article elimination process, along the 
guidelines of PRISMA. 
Table 1: Pharmacological interventions PICOS 
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Table 2: Non-pharmacological interventions PICOS  
Methodological quality of the trials 1 
Methodological quality is summarised in Tables 3 and 4. Study scores ranged from 16 to 31 with a 2 
mean score of 24 out of a possible 32 and given corresponding quality levels: excellent (27-32), good 3 
(21-26), fair (15-20) and poor (<15) adapted from previously documented ratings (13). 4 
Randomisation and Concealment  5 
Computer generated randomisation was used in 20 studies, one study (14) used manually shuffled 6 
sealed, opaque envelopes and two studies (15, 16) did not state how randomisation occurred. 7 
Sealed opaque envelopes were used to conceal randomisation in nine studies (14, 16-22). Identical or 8 
labelled syringes or masked tablets were provided immediately after randomisation by the pharmacist 9 
in seven studies (23-27).  10 
Intention-to-Treat Analysis 11 
Two studies excluded from their analysis participants with missing data who either withdrew from the 12 
study or failed to record outcome (18, 28) and one (15) did not clarify data analysis approach following 13 
drop outs.  14 
Blinding 15 
Of the seventeen pharmacological RCTs double blinding occurred in fifteen. In two studies (18, 23)only 16 
the patient was blinded to treatment. In two studies (29, 30) multiple superficial injections were 17 
compared to a single infusion and no blinding occurred. 18 
Of the acupuncture studies one (31) attempted to blind the participants by providing sham 19 
acupuncture, one (32) blinded the outcome assessors and acupuncturists to pharmacological therapy 20 
and one (14) made no attempt at blinding. The outcome assessors only were blinded in the 21 





Table 3: Downs and Black scores of pharmacological studies.  25 
Table 4: Downs and Black scores of non-pharmacological studies.  26 
Pharmacological studies 27 
Twenty-one studies, including 3482 patients, investigated the pharmacological management of back 28 
pain in the ED. Mean methodological score was 26 (Table 3).  There were n=11 studies of excellent 29 
quality. N=2 (17, 20) found corticosteroids to be beneficial in LBP with sciatica, but not LBP without 30 
sciatica. When considering the use of oral and topical non-steroidal anti-inflammatory drugs 31 
(NSAIDs) in the management of LBP without sciatica n=3 studies (23, 24, 26) found Naproxen to be 32 
superior alone when compared to combination pharmacotherapy, the addition of paracetamol to 33 
ibuprofen compared to ibuprofen alone did not improve outcomes after one week(34), and n=1 34 
study found the application of Ketoprofen gel in addition to intravenous (IV) Dexketoprofen to be 35 
superior to placebo (27). IV Dexketoprofen NSAID) was as effective as IV Paracetamol and IV 36 
Morphine in patients with LBP without neurological deficit(19) in n=1 study. N=4 (23, 24, 26, 35) 37 
studies concluded that muscle relaxants are not helpful in the management of LBP without sciatica 38 
and there were no studies investigating the use of muscle relaxants in LBP with sciatica. IV Morphine 39 
was found to be superior to IV paracetamol in patients with LBP with sciatica and the same adverse 40 
effect profile in n=1 study (21). N=1 study found that at least fifty trigger point injections of a 41 
combination of Thiocolchicoside, Lidocaine and Tenoxicam was more effective in reducing pain up to 42 
one hour compared so a single dose of IV Dexketoprofen (29) (Table 5). 43 
Studies included male and female adults aged 18 and over. Thirteen studies included only patients 44 
with acute and severe pain identified by duration of pain and minimum score on a pain Visual 45 
Analogue Scale (VAS) or numerical pain rating scale (NPRS), however minimum scores were 46 
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inconsistent throughout the studies. Six studies excluded patients without sciatica (17, 20, 21, 28, 47 
29, 36), twelve studies excluded patients with sciatica (18, 19, 23-27, 30, 34, 35, 37) and the 48 
remaining studies did not specify the presence or absence of sciatica in their inclusion or exclusion 49 
criteria.  50 
All studies recorded short-term outcomes measures ranging from 15 minutes to 7 days including 51 
pain severity, function, adverse events, use of rescue analgesia, EDLOS, patient satisfaction and 52 
healthcare utilization.  Long-term outcomes were measured in 16 studies ranging from one week to 53 
three months. 54 
 55 
Table 5: Grouped positive and negative finding of pharmacological studies 56 
Non-Pharmacological studies 57 
Five studies, (2034 patients) investigated the non-pharmacological management of back pain in the 58 
ED. Mean methodological score was 21.6 (Table 4). Two fair quality studies (24, 35) concluded that 59 
Physiotherapy assessment and treatment was superior to standard care on discharge and at 1 60 
month. One excellent quality study (32) concluded that acupuncture does not enhance pain relief 61 
when alone or combined with pharmacological management and two acupuncture studies (16, 31) 62 
of fair quality concluded that acupuncture is effective for short-term pain relief (Table 6). 63 
Studies included male and female adults aged 18 and over. Only one study specified a minimum pain 64 
score for inclusion criteria. Two physiotherapy studies (24, 35) included patients with back pain with 65 
or without radicular pain. Three acupuncture studies included patients with back pain only.  66 
All studies recorded short-term outcomes and four studies recorded follow up outcomes ranging 67 
from 48 hours (32) to 6 months (24). The outcome measures focused on pain, function and adverse 68 
events. Two studies (32, 35) considered EDLOS and ongoing resource use, such as admission rate 69 
and rescue analgesia. 70 
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Table 6: Grouped positive and negative finding of non-pharmacological studies 71 
Discussion 72 
The purpose of this systematic review was to determine the evidence base for the therapeutic 73 
management of adults attending the ED with back pain with or without sciatica.  74 
Low back pain with or without sciatica is recognized as a major financial burden because of the 75 
resources needed for its management, including imaging, increased ED length of stay, ongoing 76 
analgesic management, healthcare utilisation and potential hospital ward admission(4). 77 
Despite the studies reviewed spanning eight countries there are no data to determine the 78 
prevalence or management of LBP in the ED in the UK.   79 
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) 80 
Findings from this review that NSAIDs are as effective alone than when combined with other 81 
pharmacology (23, 26, 27, 38, 39) are consistent with the recommendations of others (40, 41). It is 82 
recommended that oral NSAIDs should be considered first in the ED management of patients with 83 
back pain and that the addition of opioids or muscle relaxants do not significantly affect pain-84 
relieving qualities (40).  The National Institute of Clinical Excellence (NICE) (41) goes further and 85 
states that patients with LBP should be managed in primary care without the need to burden an 86 
already overstretched ED. 87 
None of the studies comparing Naproxen to muscle relaxants sub-classified patients into those with 88 
spasm and those without. Therefore, the effect of adding muscle relaxants in the presence of muscle 89 
spasm was not established.  90 
Two studies of varied quality indicate that IV NSAIDs are as effective as other parenteral drugs 91 
without a significant adverse effect profile (19, 28); however, no studies compare the efficacy of IV 92 
to oral in terms of pain relief, EDLOS and ongoing resource use. 93 
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One high quality study (27) concluded that adding Ketoprofen gel to IV dexketoprofen significantly 94 
improved pain relief at 30mins; however, functional outcomes, long-term outcomes or EDLOS were 95 
not reported. 96 
Opioids 97 
While there is no doubt that IV morphine is effective in the management of back pain in the ED, 98 
there is conflicting evidence regarding its superiority (19, 21). Both studies reported similar adverse 99 
events including nausea, vomiting and dizziness. Due to rare but unpredictable serious adverse 100 
events (42), patients require lengthy monitoring post IV administration of morphine resulting in 101 
potentially higher EDLOS than that of other analgesia. Unfortunately, neither studies included EDLOS 102 
as an outcome measure making it impossible to determine this. 103 
Acetaminophen-codeine is found to be of no greater benefit to pain relief when combined with 104 
NSAIDs and has a greater adverse effect profile (23, 39) making it a poor choice of management.   105 
Tapentadol and Tramadol were both effective resulting in significant pain reduction after 7 days and 106 
3 months in one moderate quality study (43). Patients who received Tapentadol demonstrated 107 
reduced re-attendance rates 30 days following discharge. 108 
Although there seems to be a place for opioids in this population these results are in line with clinical 109 
guidance advising use be reserved for severe and disabling pain that is not controlled with first line 110 
management (7). Essential considerations for prescribing opioids on discharge must include 111 
increasing rates of opioid prescription in primary care and the association with abuse, serious 112 
adverse effects and premature death (38), particularly in this patient group where a significant 113 
proportion will continue to access healthcare in the long term. 114 
Corticosteroids 115 
For patients presenting with back pain in the absence of neurological deficit oral prednisolone was 116 
not effective in the reduction of pain and resulted in more medical management and greater 117 
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number of days off work (34). For patients presenting with back pain without radicular symptoms 118 
there were no benefits to intra-muscular (IM) methylprednisolone when administered in addition to 119 
standard care (28).  120 
For patients presenting with radicular back pain in the ED some benefits pertaining to the use of 121 
corticosteroids have been documented. IV dexamethasone significantly reduced 24-hour pain and 122 
EDLOS (19) in one high quality study, while IM methylprednisolone significantly reduced disability 123 
and analgesic use in a study with poor selection bias and no reported power calculation. This 124 
observation needs to be investigated further, perhaps leading to the stratification of low back 125 
patients based on radicular symptoms. 126 
Physiotherapy 127 
Physiotherapists have become increasingly common in the ED team, particularly in the UK, USA and 128 
Australia (12).  129 
The utilization of physiotherapists with advanced competencies as first contact practitioners in the 130 
ED has shown positive results in one moderate quality study (35). Patients assessed by advanced 131 
musculoskeletal physiotherapists had less EDLOS and were less likely to be admitted to a hospital 132 
ward compared to patients seen by doctors or nurse practitioners, without evidence of re-133 
attendance.  134 
Implementing physiotherapy management in the ED for patients with and without sciatica resulted 135 
in significantly improved pain and function on discharge and 1 month follow up compared to usual 136 
care (24).  The intervention group received advice, pain education and reassurance as well as 137 
practical guidance on returning to usual activities and coping strategies in line with NICE guidance 138 
(41). Although this study supports early physiotherapy intervention in the ED due to difficulty 139 
blinding participants and physiotherapists and a lack of power calculation, a moderate risk of bias 140 




In one high quality study, acupuncture was found to be of no benefit in addition to 143 
pharmacotherapy (32). The group receiving acupuncture in isolation required significantly more 144 
rescue analgesia and were more likely to be admitted onto a hospital ward. These findings suggest 145 
that acupuncture is not likely to enhance the management of back pain in the ED. 146 
Strengths and limitations of the study 147 
This was a rigorous systematic review following PRISMA guidance with prior publication in 148 
PROSPERO. Two reviewers independently searched the databases, extracted the data and reviewed 149 
the literature for quality with third and fourth arbiters. An evidence-based risk of bias tool was used 150 
to evaluate the heterogeneous studies and a narrative approach to reporting the findings was taken 151 
according to recommendations.  152 
Despite this, limitations existed. The reviewers were not blinded to publication information (e.g. 153 
authors and institution names). Despite our best attempt at being systematic and complete in our 154 
searches, we excluded five articles that were not in English. These two issues potentially introduce 155 
cultural, language and/or publication bias. 156 
Conclusion 157 
This review has identified that there is a lack of understanding of the prevalence of back pain 158 
attendances in the UK ED. Prior to undertaking trials investigating the management of LBP in the ED 159 
in the UK basic epidemiological data on numbers attending is required.  160 
The available literature regarding the therapeutic management of acute low back pain with or 161 
without sciatica in the ED has been summarised in this review. The evidence suggests for patients 162 
presenting with back pain and no radicular symptoms Naproxen should be considered as first line 163 
pain relief. IV morphine, paracetamol or dexketoprofen could be considered in this group in rare 164 
cases of severe pain where first line treatment is unsuccessful.  165 
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For patients presenting with radicular symptoms, first line analgesic management is not clear from 166 
the literature. In cases of severe pain IV corticosteroids could be considered. 167 
The literature indicates physiotherapy assessment and interventions may be effective in improving 168 
EDLOS, pain and functional outcomes in LBP patients with and without radicular symptoms. 169 
However, in order to establish whether physiotherapy can be recommended as part of an evidence-170 
based management protocol for the treatment of acute LBP with or without sciatica in the ED, high 171 
quality trials are required. 172 
Further studies to investigate the pharmacological management of LBP without radicular symptoms 173 
are not recommended.  174 
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Additional records identified 
through other sources  
(n = 0) 
Records screened  
(n = 2384) 
Records excluded title, 
abstract or duplicates  
(n = 2232) 
 
Full-text articles assessed 
for eligibility  
(n = 152) 
 
Studies included in 
qualitative synthesis  
(n = 26) 
Full-text articles excluded  
(n =126) 
Reasons: 
Not back pain 5 
Not ED setting 9 
Chronic pain 18 
Reviews 2 
Not treatment back pain 1 
Investigations 34 
Clinical commentary 6 
Mixed population unable to 
extract back pain data 10 
Conference abstracts 9 
Unable to contact author 5 
Observational 24 











Participants Interventions Comparisons Outcomes 









Median age: 36 
Female: n=56 
Acute LBP with 
confirmed disc 
herniation and 
positive straight leg 
raise 
Group 1:  
>50 mesotherapy 
injections 1-3mm 









50mg dexketoprofen in 
100cc isotonic solution 
IV for 5 minutes. 
Mean delta values of pain VAS score reduction: 
15 minutes: G1 2.13 (SD 1.46), G2 1.32 (SD 0.85) p=0.001 
30 minutes: G1 3.70 (SD 1.98), G2 2.18 (SD 1.08) p<0.001 
60 minutes: G1 4.68 (SD 2.14), G2 2.97 (SD 1.15) p<0.001 
24 hours: G1 6.08 (SD 1.87), G2 3.92 (SD 1.43) 
 












Radicular low back 
pain. 
Female: n=28  
Aged 18-55. 












Group 2 (G2):  
2ml IV 0.9% sodium 
chloride.  
 




Pain VAS: 1.86 point greater reduction in group 1 (95% CI 0.3 to 3.4, p=0.02) 
EDLOS: Shorter in G1 (median 3.5 vs 18.8hrs, p=0.049) 
SLR ROM: G1: 14.7° greater improvement (95% CI 1.3 to 34.3, p=0.04) 
ODI: -3 mean diff (95% CI -15.1 to 9.1 p=0.62). *  
6 weeks:  
Pain VAS: Significant improvement in pain both groups. G1: -4.28 (95% CI -6.2 
to -2.54, p<0.001). G2: -2.83 (95% CI-4.37 to -1.28, p<0.001). * 
ODI: 2.9 mean diff (95% CI -13.4 to 19.3, p=0.72) * 
Ability to return to normal activities: 74% vs 60%, p=0.3. * 














Group 2:  
0.1mg/kg, up to 10mg 
IV morphine in 150ml 
normal saline solution 
over 30 minutes 
2 hours: 
Pain VAS: G1 vs G2: 4mm less reduction in pain (95%CI -3 to 11) p=0.26 












over 30 minutes 
EDLOS: G1 vs G2: 78mins increase (95%CI 16-140) p=0.01. Significant increase 
Gp1. 
 
Patient satisfaction VAS: G1 vs G2: 4mm less (95%CI -5 to 13) p=0.39. * 
Adverse events: G1 vs G2: 73.1% increase (50-85) p<0.001. Significantly more 
drowsiness and sedation in G1. 








LBP (4-pt VRS: 
mod/sev). 
Acute (last week).  
Female: n=54. 





Group 1:  
IV paracetamol 1g 
in 100ml saline 
solution.  
 






IV dexketoprofen 50mg 
in 100mg saline solution 
15 mins: 
Pain VAS: G1 vs G2: 11.3 mean diff (95% CI 1 to 22). Gp2 vs Gp3: 15.3 mean 
diff (95%CI -25 to 6). G1 vs G3: 4 mean diff (95%CI -13 to 5). * 
30 mins: 
Pain VAS: G1 vs G2: 3.8 mean diff (95%CI -6 to 14). G1 vs G3 7.4 mean diff 
(95%CI -18 to 3). G2 vs G3: 11.2 mean diff (95%CI 2 to 21). * 
Rescue analgesia:  
Group 1: 17.4%, group 2: 4.4%, group 3: 15.2%. P=0.135. * 
Adverse effects: 
Group 1: 8.7%, group 2: 15.5%, group 3: 8.7%. P=0.482. * 







Short-term: n=72.  
Long-term: n=61. 
LBP  




Age: 18-55  
Normal blood 
markers  
No muscle relaxant 
or NSAID use in past 
12 hrs 
Group 1:  








TTD 3, 7 days 
 
Rescue: Oral 20 x 
275mg naproxen 






phenyramidol ampoule.  
 
Chronic phase: Placebo.  
 
Rescue analgesia: Oral 2 
x 275mg naproxen 
sodium TTD max 4  
Acute phase 2hrs: 
Pain VAS: Pain reduction between groups p=0.624. * 
 
Pharmacokinetic parameters: * 
 
Adverse effects: 11% of patients in each group suffered mild/mod. 
 
Chronic phase 1 week:   
Rescue analgesics: Less than 1 per day. *   
Median global evaluation score: “Mildly effective” patients and physicians 
both gps.  
Adverse effects: 7/38 patients in group 2 showed elevated liver enzymes, 
resolving with no treatment 7 days later. 






24hr history of LBP 
Female: n=24  
Age: 18 to 55 
Pain >5 VAS   
Group 1:  
Oral 50mg 
prednisone, and 4 
x 50mg oral 
prednisone to 
Group 2:  
Oral placebo tablet, and 
4 placebo tablets to 
take home, to use one 
per day. 
5-7 days: 
3-point pain VRS: G1 vsG2: 0.2 mean diff (95%CI -0.2 to 0.6) p=0.25. * 
Further medical care: G1 vs G2: 22% mean diff (95%CI 0 to 43%) p=0.05. 
Significantly more patients in the prednisolone group sought further medical 
care than in the placebo group. 
16 
 
(37) No neurological 
motor deficits. 
No current use of 
steroids 
take home, to use 
one per day.  
 
Analgesic therapy 








Days lost to work: G1 vs G2: 0.9 mean diff (95%CI -0.1 to 1.8) p=0.06. * 
Resumed normal activities: G1 vs G2: 0%mean diff (95%CI -23 to 23) p=1 * 
Returned to work: G1 vs G2: -1%mean diff (95%CI -22 to 19) p=0.95 * 
Patient satisfaction: G1 vs G2: 0.0%mean diff (95%CI -0.2 to 0.3) p=0.90 * 









Non radicular LBP 
<7 day History 
Female: 51 
Age: 21 to 50 





Standard care: as 
above. 
Group 2: 
IM 160mg placebo. 
 
Standard care: as above 
 
1 week: 
Past 24-hour pain NRS: 0.6 mean difference between groups (95%CI -0.9 to 
2.2) * 
RMDQ-18=0: G1 71% vs G2 74% 
Return to usual activities: G1 87% vs G2 79%. * 
Adverse effects: 24% diff btwn Gps (95% CI, 16 to 35). Worse in G1. 
% pain free patients: G1 33 vs G2 40%. * 
1 month: 
Pain NRS: 0.6 mean diff(95%CI -1 to 2.2) * 
RMDQ-18=0: G1 77% vs G2 74%. * 
Return to usual activities: G1 85% vs G2 80%. * 











<7 day history 
Female: n=43 
Age: 21 to 50 
Positive SLR (30-70°) 







Standard care: 14 
x 500mg 
naproxen twice 
daily, 14 x 
oxycodone 
5mg/acetaminop
hen as needed, 
LBP instruction 
sheet. 
Group 2:  
IM 160mg placebo. 
 
 Standard care: 14 x 
500mg naproxen twice 
daily, 14 x oxycodone 
5mg/acetaminophen as 
needed, LBP instruction 
sheet 
1 week: 
Past 24-hour pain NRS: G1 vs G2: 1.1 mean reduction (95%CI -0.5 to 2.8) 
p=0.16.* 
Disability self report: G1 vs G2: 19% reduction (95%CI -4 to 42) 
Adverse effects: Gp1 vs Gp2: 32% vs 24%, (95%CI for diff 9%, -12 to 30) 
 
1 month: 
Past 24-hour pain NRS: G1 vsG2: 1.3 mean reduction (95%CI -0.2 to 2.7) 
p=0.10. * 
Disability self report: G1 vs G2: 29% reduction (95%CI 9 to 49) p=0.007. 
Significant difference between groups. 
 
Analgesic use 24 hours: G1 vs G2: 20% reduction (95%CI 0 to 40) p=0.06  

















Age: 21 to 64 
RMDQ score >5 
Group1:  
Oral 60 x 5mg 
cyclobenzaprine 
tablets, 1 or 2 
tablets every 8 
hours, as needed.   
 
Group2:  
Oral 60 x 325mg 
oxycodone 5mg/ 
acetaminophen 
tablets, 1 or 2 
tablets every 8 
hours, as needed.  
 
Both groups: Oral 
20 x 500mg 
naproxen tablets, 
1 every 12 hours 
Group3: 
Oral 60 x placebo 
tablets, 1 or 2 tablets 
every 8 hours, as 
needed.  
 
Oral 20 x 500mg 
naproxen tablets, 1 
every 12 hours. 
7 days:  
RMDQ: G1 vs G3=0.3(98.3% CI -2.6-3.2) p=0.77. G2 vs G3=1.3 (98.3% -1.5 to 
4.1) p=0.28. G1 vs G2=0.9 (98.3% CI -2.1 to 3.9) p=0.45. * 
No. day usual activity: G1=4, G2=4, G3=5.  
No. days return to work: G1=3, G2=2, G3=3.  
Worse LBP 24hrs mod/sev: G1=43%, G2=38%, G3= 49%. 
Frequency LBP (frequently/always): G1=31%, G2=30%, G3=37%.  
Use of medication: G1=62%, G2=59%, G3=68%.  
Adverse effects: G1 vs G3: 19% more adverse events (95%CI 7 to 31). 
G2 vs G3: 13% more adverse events (95%CI 1 to 25). 
 
3 months:  
RMDQ: G1 vs G3= 0.6 (-1.3 to 2.6), G2 vs G3= 0.8(-1.1 to 2.7), G1 vs G2=0.2(-
1.9 to 2.2) mean % diff (CI 95%). 
Worse LBP 72hrs % (mod/sev): G1=27, G2=21, G3=28.  
Frequency LBP 72hrs %(freq/always): G1=12, G2=18, G3=19. Use of meds %: 
G1=26, G2=20, G3=28. 
Use of medication 72hrs: G1 vs G3: reduction of 2(95%CI-10 to 14) 
G2 vs G3: reduction of 8(95%CI -3 to 19) 
Friedman, B. 









N=114   




musculoskeletal LBP.  
RMDQ>5.  




twice per day. 
 
Diazepam 5mg 
taken as 1 or 2 
tablets every 12 
hours for 7 days. 
Group 2:  
Naproxen 500mg 
tablets taken twice per 
day.  
 
Placebo taken as 1 or 2 
tablets every 12 hours 
for 7 days. 
1 week: 
RMDQ: Mean improvement: G1 11(95%CI 9 to 13) vs G2 11 (95%CI 8 to 13). * 
Median days return to usual activity: Diff between groups: -0.4 (95%CI -0.6 to 
1.4) * 
Worst LBP 24hrs: 4 item ordinal scale. Diff between groups: -10 (95%CI -26 to 
7) * 
Frequency of LBP 24hrs: 3 item ordinal scale. Diff between groups: -6 (95%CI -
25 to 12) * 
Use of medication: Diff between groups: 0 (95%CI -19 to 18) * 
Adverse events: Diff between groups: 6 (95%CI -9 to 20) * No serious or 
unexpected adverse events. 
3 months: 
RMDQ: Median score G1: 0, G2: 0. Diff between groups: -2 (95%CI -4.2 to 
0.3)* 
Worse LBP 72hrs: Diff between groups: -3 (95%CI -15 to 9) * 
Frequency LBP 72hrs: Diff between groups: 5 (95%CI -10 to 20) * 




















musculoskeletal LBP  
RMDQ >5 
Pain duration <2 
weeks 
Group 1:  
Naproxen 500mg 
twice per day. 
Orphenadrine 
100mg twice per 
day.  
 
Group 2:  
Naproxen 500mg 
twice per day. 
Methocarbamol 
750mg as 1 or 2 
tablets 3 times 
per day. 
Group 3:  
Naproxen 500mg twice 
per day. 
 
Placebo randomised to 
match the dosing 
patterns of group 1 and 
group 2. 
1 week: 
RMDQ: Mean improvement: G1: 9.4 (95%CI 7.4 to 11.5), G2: 8.1 (95% CI 6.1 
to 10.1), G3: 10.9 (95% CI 8.9 to 12.9. * 
Mean diff: G1 vs G3 1.5 (95%CI -1.4 to 4.3), G2 vs G3 2.8 (95%CI 0 to 5.7). 
Median days until usual activities: Differences: G1 vs G3: 0.2 (95%CI -0.7 to 
1.0), G2 vs G3: 0.3 (95%CI -0.6 to 1.1), G1 vs G2: 0.1 (95%CI -0.8 to 1.0). * 
Worst LBP 24Hrs (%): Differences: G1 vs G3: 1 (95% CI -14 to 16), G2 vs G3: 5 
(95% CI -11 to 20), G1 vs G2: 5 (95% CI -10 to 20). * 
Frequency of LBP 24hrs (%): Differences: G1 vs G3: 4 (95%CI -12 to 20), G2 vs 
G3: 7 (95%CI -8 to 23), G1 vs G2: 11 (95%CI -4 to 27). * 
Use of medication 24hrs (%): Differences: G1 vs G3: 4 (95%CI -12 to 20), G2 vs 
G3: 7 (95%CI -8 to 23), G1 vs G2: 11 (95%CI -4 to 27). * 
More than 80% of participants did not visit health care providers.   
Adverse events: G1: 7%, G2: 14%, G3: 13%. 
3 months:  
RMDQ (median): G1: 0 (IQR 0 to 4), G2: 0 (IQR 0 to 13), G3: 0 (IQR 0 to 8).*. 
Worst LBP 72hrs (% mild/none): G1: 55, G2: 58, G3: 55. * 
Friedman, B. 









Mean age: (39) 
Non-traumatic, non-
radicular, 
musculoskeletal LBP  
RMDQ >5 





Group 2 (n=80): 
600mg ibuprofen 
plus 10-20mg 
baclofen orally 8 
hourly. 
 






Group 4 (n=80): 
600mg ibuprofen 
plus tizanidine 2-4 
mg orally 8 
hourly. 
Group 1 (n=80): 
600mg ibuprofen plus 
placebo orally 8 hourly. 
48 hours: 
% severe LBP: G1 62%, G2 48%, G3 55%, G4 47%. 
% frequent LBP: G1 38%, G2 30%, G3 36%, G4 31%. 
Medication use: G1 94%, G2 91%, G3 91%, G4 90%. 
Resumed usual activities: G1 47%, G2 51%, G3 41%, G4 46% 
 
1 week: 
Mean improvement RMDQ: G1 11.1 (95%CI 9.0-13.3), G2 10.6 (95%CI 8.6-
12.7), G3 10.1 (95%CI 8.0-12.3), G4 11.2 (95%CI 9.2-13.2). 
% severe LBP: G1 30, G2 33, G3 37, G4 33. 
% frequent LBP: G1 16, G2 27, G3 32, G4 24. 
Medication use: G1 63, G2 62, G3 64, G4 63. 
Median days until usual activities: G1 2(IQR 2-7), G2 4(IQR 2->7), G3 3(IQR 2-
7), G4 3(IQR 2-7). 
 










Mean age: 41 
Non-traumatic, non-
radicular, 
musculoskeletal LBP  
RMDQ >5 








orally 6 hourly. 
Group 2: (n=60) 
600mg ibuprofen plus 
placebo orally 6 hourly. 
48 hours: 
RMDQ improvement: btwn G difference 0.1 (95%CI -3.4 to 3.5) 
% mild LBP: btwn G difference 3 (95%CI -15 to 21) 
% rare vs frequent LBP: btwn G difference 2 (95%CI -15 to 19) 
% no use of medication: btwn G difference 7 (95%CI 7 to 21) 
 
1 week: 
Median RMDQ: G1 10 (IQR 0 to 20), G2 12 (IQR 0 to 18) 
%mild LBP: Btwn G difference 0 (95%CI -17 to 17). 
% rare vs frequent LBP: btwn G difference 1 (95%CI -18 to 19) 
% no use of medication: btwn G difference 2 (95%CI -11 to 20) 
Median days until usual activities: btwn G difference 0.6 (IQR -0.5 to 1.7) 
No visit to health care provider %: btwn G difference 7 (95%CI -4 to 17) 
Guillen-
Astete, C. A. 









Back pain  
Group 1: significantly 
younger, less men, 
more comorbidities, 
significantly higher 
VAS and significantly 
lower SF-36. 
Group 1 (n=91):  
Tapentadol. 
23 received 25mg 






Group 2 (n=641): 
No tapentadol. 
414 received tramadol: 
44 TDD  ≤37.5mg/d.  
141 TDD >37.5, ≤100mg.  
172 TDD >100mg, 
≤200mg. 
57 TDD >200mg. 67.2%. 
 
431 also received NSAID 
7 days: 
Pain VAS: G1: superior clinical evolution of pain (VAS and SF-36) than G2. 
P<0.0001. 
In G2 patients who received tramadol had a better clinical evolution of pain vs 
no tramadol or tapentadol: p=0.007. 
1 month: 
Reassessment: G1: 20.9% vs G2: 50.3%. P<0.0001 (OR 0.258, 95%CI 0.147 to 
0.453). Significant reduction in reassessment in G1. 
Adverse effects 
G1: 3(3%) patients attended for adverse effects. G2: 3 (5%) patients attended 
for adverse effects. * 











point verbal rating 
scale) 
Female: n=26 
Age: 18 to 60 
Weighing >50kg 
Discharged within 2  







then the same 
every 4 to 6 hours 
as needed, up to 





Group 2:  
Oral 600mg 
acetaminophen/ 60mg 
codeine, then the same 
every 4 to 6 hours as 
needed, up to 6 daily 
doses. 
6 Hours: 
Pain VAS: Peak pain intensity difference in both groups was 2.2hrs. G1 -25.5 
(SD 17.9) G2 -27.7 (SD 17.9) no difference between groups. 
1 week: 
Pain VRS: Day 4: “a lot” or “complete” achieved by G1 53% (95%CI 40 to 66) 
and G2 55% (95%CI 42 to 68). No significant difference between groups at 
one week. 
Functional capacity: Both groups improved, no difference between groups 
(74% (62-86) vs 73% (61-74) reported “moderately” or “severely impaired” on 
day 1; 67% (55-79) vs 62% (50-74) on day 4 reported “No” or “mild 
impairment”. 
1 month:  
20 
 
Overall drug rating: No significant difference between groups G1: 48% vs G2:  
45% “very good” or “excellent. G1: 29% vs G2: 18% good, 23% vs 37% “fair” or 
“poor”.  
Adverse effect: G2 2: 34% (95%CI 22-46) vs G1 64% (95%CI 52-76) p=0.0005. 
Kocak, A. O. 







Mean age: 43 
<48 hour onset non 
radicular LBP 
Presence of at least 1 
trigger point 
Group 1: 
Small amounts of 
local anesthetic 
(2% lidocaine, 2.5 
cc from 100 mg-5 
cc of 
ampoule with 2.5 
cc saline) injected 
into trigger points 
Group 2: 
50 mg dexketoprofen in 
100cc isoltonis solution 
over 5 minutes. 
Mean pain VAS:  
5 minutes: G1 2.77 (SD 2.81), G2 6.22 (SD 2.11) p<0.0001 
10 minutes: G1 1.45 (SD 2.15), G2 5.22 (SD 2.41) p<0.0001 
15 minutes: G1 0.82 (SD 1.71), G2 4.25 (SD 2.41) p<0.0001 
30minutes: G10.55 (SD 1.6), G2 3.28 (SD 2.44) p<0.0001 
60 minutes: G1 0.41 (SD 1.3), G2 2.59 (SD 2.37) p<0.0001 
Respond to treatment (yes/no) G1 21/1, G2 20/12 p=0.008 
 
No adverse events. 








Severe LBP (axial +/- 
radiculopathy) 
Spondylosis 
Refractory to NSAIDs, 








attempts for pain 









Group 2:  
After maximal attempts 
for pain relief in the ED 
failed. 
 
Hospital admission for 
pain relief. 
2 weeks: 
Cost of care: G1 $4,800 (SD 2000) vs G2 $33,000 (SD 14000) p<0.001. 
Significantly lower in G1. 
EDLOS: G1 8hrs (SD 3.6) vs G2 13hrs (SD4.2) p<0.002. Significantly less in G1. 
 
Medication use: G1: 1/4 of hydromorphone dose and 1/3 of morphine dose 
while in ED, p<0.0001; 1/10 of hydromorphone dose and 1/18 of oxycodone 
dose prescribed, p<0.0001. 
  
Consultant utilisation: G1 3 vs G2 18 times, p<0.0001. 
Admission time: G1 mean 0 days vs G2 mean 5 days, p<0.002. 
Serinken, M. 







Age: 21 to 65 
(mean=42.9) 
Sciatica and positive 
SLR 
49.3% male 





100mls saline.  
 
Group 2:  
IV paracetamol 
(1g) in 100mls 
saline.  
 
Group 3:  
100mls normal saline.  
 
 Fentanyl 1ug/kg rescue 
drug at 30mins if 
needed. 
30mins: 
Pain VAS: Median changes: G1 54mm (95% CI=50-60mm), G2 29mm (95% 
CI=28-34mm), G3 12.5mm (95% CI 10-15).  
 
Median changes between groups: G1 vs G2 25mm (95% CI=20-29mm), G1 vs 
G3 41mm (95% CI=37-45mm), G2 vs G3 16mm (95% CI=12-2-mm). 
 
Rescue fentanyl: G1 6% (95%CI=2-13.2), G2 18% (95% CI 10.7-28.5), G3 80% 
(95% CI 63-99). 
 




rescue drug at 
30mins if needed. 
Serinken, M. 








Age: 18 to 65 (35+/-
12)  
56% male 
Mechanical LBP (no 
sciatica) 
 Pain <24hrs. VAS 
>40mm. 




2g of 2.5% 
ketoprofen gel 
over approx 5cm 
diameter. 
Group 2:  
50mg IV dexketoprofen. 
 
2g of placebo gel over 
approx 5cm diameter. 
15 mins: 
Pain VAS: G1: mean reduction 27 (SD 13), G2: mean reduction 28 (SD13) 
Mean diff: 0.5 (95%CI -4 to 5) p=0.8 
30mins: 
Pain VAS: G1: mean reduction, G2: mean reduction. Mean diff: 16 (95%CI 10-
21) p=0.000. Significant improvement in G1. 
Rescue drug: G1 3%, G2 14%.  
Adverse events: 1 patient per group. 







Acute radicular LBP 
Female: n=19  
Age: 15 to 55 
Pain >25mm VAS 
Group 1:  
IV 100mg 
lidocaine over 2 
minutes, followed 
by 10cc normal 
saline flush 
Group 2:  
IV 30mg ketorolac over 
2 minutes, followed by 
10cc normal saline flush 
60 mins: 
Pain VAS: G1: median reduction 8 (95%CI 0 to 23) p=0.003. G2: median 
reduction 14 (95%CI 0 to 28) p=0.007. P=0.835. * 
Clinical significance accepted by study: 13mm reduction in VAS. 
Rescue medication: G1 vs G2: 67% vs 50% p=0.35. * 
1 week: 











Warrants parenteral  
Age: over 18 
Pain VAS >70mm  
Group 1:  
IM 1mg/kg 
meperidine 
Group 2:  
IM 60mg ketorolac 
60 mins: 
Pain VAS: Ketorolac 7mm (36 vs 29) less Pain Intensity Decrease than 
meperidine; 95% CI -15 to 2.6). Significant pain reduction in both groups. * 
Rescue analgesia: 37% vs 35%, (OR 0.47-1.74 95% CI) * 
Sedation: Sedation level by 3-point ordinal scale, adverse effects, rescue 
analgesia, 5-point patient satisfaction scale. 
Satisfaction: 74% vs 68%. * 
Adverse effects: G1 (41/75) vs G2 (8/80) 95%CI .27 to .63. More sedation in  
G1 (71% vs 24% “sedated” or “asleep, OR 3.54-17.4 
Key: SD= Standard Deviation, CI= Confidence Interval, Mg= Milligrams, VRS= Visual Rating Scale, NRS= Numerical Rating Scale, G= Group, OR= Odds Ratio, ED= Emergency Department, IV= Intravenous, 217 
IM=Intramuscular, LBP= Low back Pain, *No significant difference between groups, ICD= International Classification of Disease Revision Codes, EDLOS= Emergency department length of stay, ODI= Oswestry disability 218 
index, NSAID= Non-steroidal anti-inflammatory, TDD= total daily dose, SLR ROM=straight leg raise range of movement, VAS=visual analogue scale, RMDQ= Roland Morris Disability Index 219 







Participants Interventions Comparisons Outcomes 
Cohen, M.M. 








N= 528 (270 51% 
with LBP) 
Age: mean 41 years 
47% female 
Pain VNRS >4 
 
 











minutes apart to 
maintain blinding. 












NSAID, IV morphine. 
1 hour 
Pain NRS: Mean decrease: G1 1.9 (SD 2.3) G2 2.2 (SD2.2) G3 2.0 (SD2.3)* 
p=0.29. 
Rescue analgesia: G1 45 (25%) G2 27 (15%) G3 26 (15%) Significantly more 
use in G1 p=0.016. 
Satisfaction: * p=0.91 




Admission rate: G1 27(19%) G2 13(9.2%) G3 20(15%). Significantly more 
admissions in G1 p=0.07 
ODI mean difference: G1 27.9 (12.7), G2 27.4 (11.5), G3 29.3 (11.1)* p=0.52. 
 
No statistically significant change in any other outcome measure after 1 or 
48 hours.  











Age: >18 years 
(mean 41) 
56% female 
Acute or acute on 
chronic LBP 











Group 2:  
Standard care 
(discretion of treating 
physician) 
Post intervention 
Time to get up and go test: G1 21.3 (95% CI 18.2-24.5) G2 19 (95% CI 15.6-
22.5) *p=0.33. 
LBP NRS: G1 5.2 (95% CI 4.2-6.2, G2 6.9 (95% CI 5.7-8.3). G1 significantly 
lower p=0.04. 
Leg pain NRS: G1 1.4 (95%CI 0.1 to 2.7) G2 2.2 (95%CI 0.7 to 3.5)* p=0.43 
 
*flexion, extension  
 
EDLOS, medication and adverse events were not reported. 






Acute low back 
pain +/- leg referral  
Female: n=67  
Group 1: 
Stay active advice, 






training, walking aids 
as indicated. 
Discharge from ED: 
Pain NRS: Between group diff: -1.6(97.5%CI -2.3 to 0.8) Significantly less pain 
in group 1. 
RMDQ: Between group diff -0.3 (-2.8 to 2.2) 





Age: 19-88 (mean 
50) 
No previous 
episode of acute 
low back pain in 
the previous 6 
months 
mobility training, 

















Patient satisfaction: Between group diff 2.1 (97.5%CI 1.2 to 2.9)  
SF-12P: between group diff -2 (-6 to 2) 
SF-12M: between group diff 5 (0.3 to 9) 
1 month: 
Pain NRS: Between group diff -0.4 (-0.3 to 0.5) 
RMDQ: Between group diff -0.6 (-1.7 to 0.6) 
Satisfaction:* 
SF-12P: Between group diff -1 (-0.5 to 2) 
SF-12M : Between group diff 1 (-4 to 5) 
6 months 
*all outcome measures 



















until “De Qi” and 
stayed in place for 15 
minutes. 
Group 2: 
Fixed point sham 
acupuncture by pasting 
seed patches next to 
the set protocol points. 
After intervention: 
Pain VAS. Median reduction: G1: 3 p<0.001, G2: 1 p=0.109. Significant 
difference between groups: p<0.001 
 
Heart rate variability. * 
Adverse effects. None reported. 
 
3 days: Pain VAS. Median reduction: G1: 4 p<0.001, G2: 2.5 p=0.011.* 
p=0.181 







Age: 18-65 years 
(42) 
50% female 




Seen by AMPs who 





Seen by non-AMP 




EDLOS: G1 141 mins G2 175min. Significantly less in G1 (p<0.001). 
Admissions rate: G1 36 G2 258. Significantly less in G1 (p<0.001).  
 
Audit period 
Re-present: * 24hrs, 48hrs, 1 week, 1 year (p=0.26) 
Key: G= Group, ED= Emergency Department, IV= Intravenous, IM=Intramuscular, LBP= Low back Pain, *No significant difference between groups, ICD= International Classification of Disease Revision Codes, EDLOS= 221 
Emergency department length of stay, ODI= Oswestry disability index, NSAID= Non-steroidal anti-inflammatory, TDD= total daily dose, SLR ROM=straight leg raise range of movement, VAS=visual analogue scale, 222 













Table 3: Downs and Black scores of pharmacological studies.  232 















Balakrishnamoorthy et al 
(2015) (17) 
10 3 7 6 5 31 Excellent 
Friedman et al (2006) (25) 10 3 7 6 5 31 Excellent 
Friedman et al (2019) (35) 10 3 7 6 5 31 Excellent 
Friedman et al (2015) (44) 11 3 6 5 5 30 Excellent 
Friedman, Irizarry et al 
(2017) (24) 
10 3 6 6 5 30 Excellent 
Friedman et al (2020) (34) 10 2 7 6 5 30 Excellent 
Serinken, Eken et al (2016) 
(27) 
9 3 7 6 5 30 Excellent 
Friedman, Ciewski et al 
(2018) (26) 
10 3 5 5 5 28 Excellent 
Akbas et al (2019) (29) 10 3 4 6 5 28 Excellent 
Eken et al (2014) (19) 10 3 5 6 3 27 Excellent 
Serinken et al (2016) (21) 9 2 6 5 5 27 Excellent 
Guillen-Asete et al (2017) 
(43) 
10 3 4 4 5 26 Good 
Eskin et al (2014) (37) 10 2 5 5 3 25 Good 
Behrbalk et al (2014) (18) 9 1 6 3 5 24 Good 
Ergün et al (2010) (15) 9 3 6 2 3 23 Good 
Innes et al (1998) (39) 11 1 6 5 0 23 Good 
Friedman et al (2008) (20) 10 3 6 3 0 22 Good 
Kocak et al (2019) (30) 10 2 5 4 0 21 Good 
Tannen et al (2014) (28) 9 1 7 4 0 21 Good 
Veenema et al (2000) (16) 9 1 7 4 0 21 Good 






Table 4: Downs and Black scores of non-pharmacological studies.  236 
















Cohen et al (2017) (32) 9 3 6 5 5 28 Excellent 
Sayer et al (2018) ( 10 3 5 4 0 22 Good 
Lau et al (2008) (33) 8 3 4 5 0 20 Fair 
Liu et al (2015) (31) 10 1 6 3 0 20 Fair 
Fox et al (2018) (14) 9 1 5 3 0 18 High 
 237 
Table 5: Grouped positive and negative finding of pharmacological studies 238 
Intervention Positive Findings (context)[quality score of 
study] 
Negative findings (context)[quality 
score of study] 
Corticosteriods IV dexamethasone: 
Reduced pain after 24 hours (-1.86 VAS 
compared to SC, radicular 
patients)[excellent] 
Reduced EDLOS (-15.3 hours compared to SC, 
radicular patients)[excellent](17) 
IM methylprednisolone:  
Not superior to SC (patients with no 
neurological deficit) [excellent](25) 
 
IM methylprednisolone: 
Lower disability (-29% compared to SC, 
radicular patients)[good] 
Less analgesic use (-20% from SC, radicular 
patients)[good](20) 
Oral prednisolone:  
More healthcare utilization (+22% 
compared to SC, patients with no 
neurological deficit)[good] 
More days lost from work (+0.9 days 
compared to SC, patients with no 
neurological deficit)[good](37) 
Epidural steroid:  
Lower healthcare cost, less medication and 
consultation utilized (Cost at $4,800, 
compared to $33,000 of SC, spondylosis 

















As effective alone than combined with 
acetaminophen-codeine, or cyclobenzaprine 
(both short and long-term, no neurological 
deficit) [excellent](23) 
As effective alone than combined with 
Diazepan (non-radicular LBP)[excellent] 
As effective alone than combined with 
orphenadrine or methacarbamol (non-
radicular LBP)[excellent](26) 
IV dexketoprofen: 
Not superior to IV paracetamol or IV 
morphine (patients with no 
neurological deficit)[excellent](19) 
ketoprofen gel:  
2g of 2.5% plus 50mg IV dexketoprofen 

















As effective as IV lidocaine, less need for 




As effective as IM meperidine, better 
adverse effect profile (71% vs 24% of 
patients sedated or asleep) [good](16) 
 
Oral Ibuprofen: 
As effective alone than combined with oral 
Baclofen, Metaxolone or Tizanidine (non-
radicular LBP) [excellent] (35) 
As effective alone than combined with oral 
paracetamol (non-radicular LBP)[excellent] 
(34) 
 
Muscle relaxants  Cyclobenzaprine: 
Not superior to Naproxen alone (no 
neurological deficit)[excellent](23) 
 Diazepam: 
Not superior to Naproxen alone (non-
radicular LBP)[excellent](24) 
 Methocarbamol: 
Not superior to naproxen alone (non-
radicular LBP)[excellent](26) 
 Phenyramidol: 
Not superior to placebo [good] (15) 
 Baclofen, Metaxolone and Tizanidine: 
Not superior to placebo when 
combined with ibuprofen (non-
radicular LBP)[excellent] (35) 
Paracetamol IV paracetamol: 
as effective as IV dexketoprofen and IV 
morphine (patients with no neurological 
deficit)[excellent](19) 
IV paracetamol: 
Inferior to IV morphine, same adverse 
effect profile (radicular 
LBP)[excellent](21) 
Opioids IV morphine: 
Superior to IV paracetamol, same adverse 
effect profile (radicular LBP)[excellent](21) 
Acetaminophen-codeine: 
Combined with Naproxen is not 
superior to Naproxen alone (short and 
long term, no neurological 
deficit)[excellent](23) 
Not superior to oral ketorolac 
(combined with acetaminophen), worse 
adverse effect profile (64% vs 34% of 
patients experienced adverse 
effects)[good] 
Tapentadol: 
Superior to other medications used in the 
ED, less need for reassessments (back 
pain)[good] (43) 
IV morphine: 
Not superior to IV paracetamol or IV 






When combined with morphine, not 
superior to morphine alone in pain 
control, worse adverse effect profile 
(50% to 85% more sedation and 
28 
 




Mesotherapy (thiocolchicoside, lidocaine, 
tenoxicam) of minimum 50 injections: 




Superior to IV dexketoprofen (non-radicular 
LBP) [Good] (30) 
 
Key: IV Intravenous, SC Standard care, LBP low back pain, EDLOS Emergency department length of stay, IM intramuscular, VAS Visual 239 
Analogue Scale, ED Emergency Department, Mg Milligrams 240 
Table 6: Grouped positive and negative finding of non-pharmacological studies 241 
Intervention Positive findings (context) 
[Quality score of study] 
Negative findings (context) 
[Quality score of study] 
Physiotherapy Physiotherapy assessment: 
Superior to Doctor or nurse 
assessment, significantly less 
EDLOS and admissions (back pain 
+/- sciatica)[good] 
Physiotherapy intervention: 
Not superior at 6 month follow 
up. 
(back pain +/- radiculopathy)[fair] 
Physiotherapy intervention: 
Superior to SC for pain relief and 
function on discharge and 1 
month follow up (back pain +/- 
radiculopathy)[fair] 
 
Acupuncture More pain reduction than sham 
acupuncture post-treatment (2cm 
vs 0cm for sham acupuncture) no 
adverse effects [fair] 
Not superior to acupuncture 
combined with SC 
pharmacotherapy and 
pharmacotherapy alone and has 
worse admission rates and need 
for rescue analgesia 
(LBP)[excellent] 
Significant reduction in pain post-
treatment (mean 2.18, battlefield 
acupuncture, back pain) [fair] 
No difference in pain at 3 days 
[fair] 
 No significant difference in 
functional outcomes (battlefield, 
back pain) [fair] 
Key: SC Standard care, EDLOS Emergency Department, LBP Low Back Pain,  242 
 243 
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